[논문]Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea

Beom, Seung Hoon; Oh, Jisu; Kim, Tae-Yong; Lee, Kyung-Hun; Yang, Yaewon; Suh, Koung Jin; Moon, Hyeong-Gon; Han, Sae-Won; Oh, Do-Youn; Han, Wonshik; Kim, Tae-You; Noh, Dong-Young; Im, Seock-Ah

doi:10.4143/crt.2016.259

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea 원문보기

Cancer research and treatment : official journal of Korean Cancer Association, v.49 no.2, 2017년, pp.454 - 463

Beom, Seung Hoon (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea) , Oh, Jisu (Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea) , Kim, Tae-Yong (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Lee, Kyung-Hun (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Yang, Yaewon (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Suh, Koung Jin (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Moon, Hyeong-Gon (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Han, Sae-Won (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Oh, Do-Youn (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Korea<) , Han, Wonshik , Kim, Tae-You , Noh, Dong-Young , Im, Seock-Ah

Abstract ▼ AI-Helper

PurposeLetrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)–positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this studywas conducted to affirm the efficacy and toxicities of letrozole in Korean patients.Materials and MethodsThis study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medicalrecords. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity.ResultsThe median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤ 2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated.ConclusionLetrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

주제어

참고문헌 (18)

1 Ferlay J Soerjomataram I Dikshit R Eser S Mathers C Rebelo M Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 2015 136 E359 86 25220842

상세보기
2 Jung KW Won YJ Kong HJ Oh CM Seo HG Lee JS Prediction of cancer incidence and mortality in Korea, 2013 Cancer Res Treat 2013 45 15 21 23613666

상세보기
3 Wilcken N Hornbuckle J Ghersi D Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Syst Rev 2003 2 CD002747 12804433
4 Paridaens RJ Dirix LY Beex LV Nooij M Cameron DA Cufer T Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 2008 26 4883 90 18794551
5 Bonneterre J Thurlimann B Robertson JF Krzakowski M Mauriac L Koralewski P Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study J Clin Oncol 2000 18 3748 57 11078487

상세보기
6 Mouridsen H Gershanovich M Sun Y Perez-Carrion R Boni C Monnier A Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 2003 21 2101 9 12775735
7 Carlson RW Allred DC Anderson BO Burstein HJ Carter WB Edge SB Breast cancer: clinical practice guidelines in oncology J Natl Compr Canc Netw 2009 7 122 92 19200416
8 Cheang MC Chia SK Voduc D Gao D Leung S Snider J Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 2009 101 736 50 19436038

상세보기
9 Nabholtz JM Buzdar A Pollak M Harwin W Burton G Mangalik A Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 2000 18 3758 67 11078488
10 Kim Z Min SY Yoon CS Jung KW Ko BS Kang E The basic facts of Korean breast cancer in 2012: results from a nationwide survey and breast cancer registry database J Breast Cancer 2015 18 103 11 26155285
11 Mouridsen H Gershanovich M Sun Y Perez-Carrion R Boni C Monnier A Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 2001 19 2596 606 11352951
12 Gibson L Lawrence D Dawson C Bliss J Aromatase inhibitors fortreatment of advanced breast cancerin postmenopausal women Cochrane Database Syst Rev 2009 4 CD003370 19821307
13 Kataja V Castiglione M ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 2008 19 Suppl 2 ii11 3 18456744
14 Masri S Phung S Wang X Wu X Yuan YC Wagman L Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor Cancer Res 2008 68 4910 8 18559539

상세보기
15 Murphy CG Dickler MN Endocrine resistance in hormoneresponsive breast cancer: mechanisms and therapeutic strategies Endocr Relat Cancer 2016 23 R337 52 27406875
16 Finn RS Crown JP Lang I Boer K Bondarenko IM Kulyk SO The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015 16 25 35 25524798
17 Turner NC Ro J Andre F Loi S Verma S Iwata H Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 2015 373 209 19 26030518

상세보기
18 Mouridsen HT Letrozole in advanced breast cancer: the PO25 trial Breast Cancer Res Treat 2007 105 Suppl 1 19 29 17333340

LOADING...

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (18)

이 논문을 인용한 문헌

연구과제 타임라인

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

연합인증

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (18)

이 논문을 인용한 문헌

연구과제 타임라인

전체(0) 논문(0) 특허(0) 보고서(0)

전체(0) 논문(0) 특허(0) 보고서(0)

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트